Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

MLA

Ying Huang, et al. “Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE MRNA-1273 Trial.” Viruses, vol. 15, no. 10, Sept. 2023, p. 2029. EBSCOhost, https://doi.org/10.3390/v15102029.

APA

Ying Huang, Nima S. Hejazi, Bryan Blette, Lindsay N. Carpp, David Benkeser, David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly E. Janes, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Britta Flach, Bob C. Lin, Sarah O’Connell, Charlene McDanal, Amanda Eaton, … United States Government (USG)/CoVPN Biostatistics Teams. (2023). Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. Viruses, 15(10), 2029. https://doi.org/10.3390/v15102029

Chicago

Ying Huang, Nima S. Hejazi, Bryan Blette, Lindsay N. Carpp, David Benkeser, David C. Montefiori, Adrian B. McDermott, et al. 2023. “Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE MRNA-1273 Trial.” Viruses 15 (10): 2029. doi:10.3390/v15102029.